{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T15:48:28Z","timestamp":1780328908888,"version":"3.54.1"},"reference-count":121,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>T-cell lymphomas are a relatively rare group of malignancies with a diverse range of pathologic features and clinical behaviors. Recent molecular studies have revealed a wide array of different mechanisms that drive the development of these malignancies and may be associated with resistance to therapies. Although widely accepted chemotherapeutic agents and combinations, including stem cell transplantation, obtain responses as initial therapy for these diseases, most patients will develop a relapse, and the median survival is only 5 years. Most patients with relapsed disease succumb within 2 to 3 years. Since 2006, the USFDA has approved five medications for treatment of these diseases, and only anti-CD30-therapy has made a change in these statistics. Clearly, newer agents are needed for treatment of these disorders, and investigators have proposed studies that evaluate agents that target these malignancies and the microenvironment depending upon the molecular mechanisms thought to underlie their pathogenesis. In this review, we discuss the currently known molecular mechanisms driving the development and persistence of these cancers and discuss novel targets for therapy of these diseases and agents that may improve outcomes for these patients.<\/jats:p>","DOI":"10.3390\/cancers13225627","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T23:02:41Z","timestamp":1636671761000},"page":"5627","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Emerging Therapeutic Landscape of Peripheral T-Cell Lymphomas Based on Advances in Biology: Current Status and Future Directions"],"prefix":"10.3390","volume":"13","author":[{"given":"Maliha","family":"Khan","sequence":"first","affiliation":[{"name":"Department of Lymphoma\/Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Samaniego","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrick B.","family":"Hagemeister","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1646-813X","authenticated-orcid":false,"given":"Swaminathan P.","family":"Iyer","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ajh.24791","article-title":"The aggressive peripheral T-cell lymphomas: 2017","volume":"92","author":"Armitage","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","article-title":"Peripheral T-cell lymphoma","volume":"117","author":"Foss","year":"2011","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"439","DOI":"10.4103\/ijmr.IJMR_1849_17","article-title":"Peripheral T cell lymphoma","volume":"147","author":"Patel","year":"2018","journal-title":"Indian J. Med. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.beha.2009.05.001","article-title":"Gene expression profiling in lymphoma diagnosis and management","volume":"22","author":"Iqbal","year":"2009","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-3-319-99716-2_2","article-title":"Molecular and Genomic Landscape of Peripheral T-Cell Lymphoma","volume":"176","author":"Iqbal","year":"2018","journal-title":"Cancer Treat. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/ajh.25513","article-title":"Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management","volume":"94","author":"Zain","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1182\/blood-2017-11-764357","article-title":"Novel insights into the pathogenesis of T-cell lymphomas","volume":"131","author":"Lim","year":"2018","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41568-020-0247-0","article-title":"Peripheral T cell lymphomas: From the bench to the clinic","volume":"20","author":"Fiore","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0065-2776(05)87005-1","article-title":"The Biology of Human Lymphoid Malignancies Revealed by Gene Expression Profiling","volume":"87","author":"Staudt","year":"2005","journal-title":"Adv. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"10703","DOI":"10.1158\/0008-5472.CAN-07-1708","article-title":"Gene Expression Analysis of Angioimmunoblastic Lymphoma Indicates Derivation from T Follicular Helper Cells and Vascular Endothelial Growth Factor Deregulation","volume":"67","author":"Piccaluga","year":"2007","journal-title":"Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","article-title":"Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma","volume":"133","author":"Heavican","year":"2019","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1182\/blood-2011-12-396150","article-title":"Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets","volume":"119","author":"Travert","year":"2012","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood-2009-06-227579","article-title":"Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma","volume":"115","author":"Iqbal","year":"2010","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3389\/fonc.2020.00898","article-title":"Genomics of Peripheral T-Cell Lymphoma and Its Implications for Personalized Medicine","volume":"10","author":"Zhang","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev-pathol-020117-043821","article-title":"Pathogenesis of Peripheral T Cell Lymphoma","volume":"13","author":"Pizzi","year":"2018","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/ng.2916","article-title":"A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma","volume":"46","author":"Yoo","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/leu.2017.273","article-title":"Activation of RHOA\u2013VAV1 signaling in angioimmunoblastic T-cell lymphoma","volume":"32","author":"Fujisawa","year":"2017","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","article-title":"Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters","volume":"120","author":"Lemonnier","year":"2012","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/leu.2016.29","article-title":"DNMT3AR882H mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice","volume":"30","author":"Scourzic","year":"2016","journal-title":"Leukemia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1182\/blood.2019791475","article-title":"Dysregulation of the TET family of epigenetic regulators in lymphoid and myeloid malignancies","volume":"134","author":"Lio","year":"2019","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"15084","DOI":"10.1073\/pnas.1617929114","article-title":"The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development","volume":"113","author":"Lemonnier","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood-2015-05-644591","article-title":"IDH2 R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ng.2873","article-title":"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas","volume":"46","author":"Palomero","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-014-0088-y","article-title":"c-FLIP is involved in tumor progression of peripheral T-cell lymphoma and targeted by histone deacetylase inhibitors","volume":"7","author":"Zheng","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1756-8722-4-50","article-title":"The Four types of Tregs in malignant lymphomas","volume":"4","author":"Wang","year":"2011","journal-title":"J. Hematol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1038\/labinvest.3700145","article-title":"Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression","volume":"84","author":"Zhao","year":"2004","journal-title":"Lab. Investig."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2015.09.033","article-title":"An analysis of MYC and EBV in diffuse large B-cell lymphomas associated with angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma not otherwise specified","volume":"48","author":"Hoffmann","year":"2015","journal-title":"Hum. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1038\/s41375-019-0473-1","article-title":"Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling","volume":"33","author":"Watatani","year":"2019","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.leu.2404045","article-title":"Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma","volume":"20","author":"Streubel","year":"2005","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3109\/10428194.2013.807510","article-title":"The importance of Notch signaling in peripheral T-cell lymphomas","volume":"55","author":"Kamstrup","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Tiemessen, M.M., Baert, M.R.M., Schonewille, T., Brugman, M., Famili, F., Salvatori, D.C.F., Meijerink, J., Ozbek, U., Clevers, H., and Van Dongen, J. (2012). The Nuclear Effector of Wnt-Signaling, Tcf1, Functions as a T-Cell\u2013Specific Tumor Suppressor for Development of Lymphomas. PLoS Biol., 10.","DOI":"10.1371\/journal.pbio.1001430"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1073\/pnas.1608839114","article-title":"Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas","volume":"114","author":"Abate","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41379-019-0279-8","article-title":"Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified","volume":"33","author":"Laginestra","year":"2019","journal-title":"Mod. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood.2019001744","article-title":"Targeted inhibition of CD47-SIRP\u03b1 requires Fc-Fc\u03b3R interactions to maximize activity in T-cell lymphomas","volume":"134","author":"Jain","year":"2019","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.3390\/cancers6031670","article-title":"Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment","volume":"6","author":"Chanmee","year":"2014","journal-title":"Cancers"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1007\/s12032-012-0244-6","article-title":"High numbers of tumor-associated macrophages correlate with poor prognosis in patients with mature T- and natural killer cell lymphomas","volume":"29","author":"Lin","year":"2012","journal-title":"Med. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin\u2019s lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1182\/blood-2012-01-405555","article-title":"Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma","volume":"120","author":"Agnelli","year":"2012","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/leu.2014.347","article-title":"A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation","volume":"29","author":"Abate","year":"2014","journal-title":"Leukemia"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ccell.2015.03.006","article-title":"Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma","volume":"27","author":"Crescenzo","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41375-020-01093-1","article-title":"STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma","volume":"35","author":"Lobello","year":"2020","journal-title":"Leukemia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Castellar","year":"2014","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1182\/blood-2018-03-838524","article-title":"Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements","volume":"132","author":"Luchtel","year":"2018","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/blood-2014-12-614503","article-title":"Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts","volume":"127","author":"Pellegrino","year":"2016","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood-2016-09-692574","article-title":"Adult T-cell leukemia: Molecular basis for clonal expansion and transformation of HTLV-1\u2013infected T cells","volume":"129","author":"Watanabe","year":"2017","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1158\/0008-5472.CAN-13-3564","article-title":"HTLV-1 bZIP Factor HBZ Promotes Cell Proliferation and Genetic Instability by Activating OncomiRs","volume":"74","author":"Vernin","year":"2014","journal-title":"Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-4690-4-92","article-title":"HTLV-1 HBZ cooperates with JunD to enhance transcription of the human telomerase reverse transcriptase gene (hTERT)","volume":"4","author":"Kuhlmann","year":"2007","journal-title":"Retrovirology"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Yasuma, K., Yasunaga, J.-I., Takemoto, K., Sugata, K., Mitobe, Y., Takenouchi, N., Nakagawa, M., Suzuki, Y., and Matsuoka, M. (2016). HTLV-1 bZIP Factor Impairs Anti-viral Immunity by Inducing Co-inhibitory Molecule, T Cell Immunoglobulin and ITIM Domain (TIGIT). PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005372"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/ng.3415","article-title":"Integrated molecular analysis of adult T cell leukemia\/lymphoma","volume":"47","author":"Kataoka","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"6731","DOI":"10.1073\/pnas.1601537113","article-title":"Oncogenic mutations in the FBXW7 gene of adult T-cell leukemia patients","volume":"113","author":"Yeh","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/ijlh.13289","article-title":"TACC3 expression as a prognostic factor in aggressive types of adult T-cell leukemia\/lymphoma patients","volume":"42","author":"Moritsubo","year":"2020","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1038\/s41388-020-01393-x","article-title":"Autocrine HGF\/c-Met signaling pathway confers aggressiveness in lymph node adult T-cell leukemia\/lymphoma","volume":"39","author":"Totani","year":"2020","journal-title":"Oncogene"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1182\/blood-2015-08-662593","article-title":"Polycomb-dependent epigenetic landscape in adult T-cell leukemia","volume":"127","author":"Fujikawa","year":"2016","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1099\/0022-1317-75-1-77","article-title":"Clonality, expression and methylation patterns of the Epstein-Barr virus genomes in lethal midline granulomas classified as peripheral angiocentric T cell lymphomas","volume":"75","author":"Minarovits","year":"1994","journal-title":"J. Gen. Virol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41564-018-0334-0","article-title":"Defective Epstein\u2013Barr virus in chronic active infection and haematological malignancy","volume":"4","author":"Okuno","year":"2019","journal-title":"Nat. Microbiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1128\/JVI.79.7.4298-4307.2005","article-title":"Critical Role of Epstein-Barr Virus (EBV)-Encoded RNA in Efficient EBV-Induced B-Lymphocyte Growth Transformation","volume":"79","author":"Yajima","year":"2005","journal-title":"J. Virol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2009-05-221275","article-title":"Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK\/T-cell lymphoma, nasal type","volume":"115","author":"Huang","year":"2010","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.ajpath.2013.12.024","article-title":"EBV-Encoded miR-BART20-5p and miR-BART8 Inhibit the IFN-\u03b3\u2013STAT1 Pathway Associated with Disease Progression in Nasal NK-Cell Lymphoma","volume":"184","author":"Huang","year":"2014","journal-title":"Am. J. Pathol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/leu.2009.3","article-title":"Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies","volume":"23","author":"Iqbal","year":"2009","journal-title":"Leukemia"},{"key":"ref_62","first-page":"1","article-title":"Activating mutations of STAT5B and STAT3 in lymphomas derived from \u03b3\u03b4-T or NK cells","volume":"6","author":"Jiang","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 expression in peripheral T-cell lymphomas","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1038\/bcj.2017.85","article-title":"Understanding CD30 biology and therapeutic targeting: A historical perspective providing insight into future directions","volume":"7","author":"Pileri","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3324\/haematol.2012.081935","article-title":"CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features","volume":"98","author":"Bisig","year":"2013","journal-title":"Haematologica"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.hoc.2019.04.002","article-title":"Peripheral T-Cell Lymphoma","volume":"33","author":"Ng","year":"2019","journal-title":"Hematol. Clin. N. Am."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1182\/blood-2013-12-516245","article-title":"How I treat the peripheral T-cell lymphomas","volume":"123","author":"Moskowitz","year":"2014","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: An analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/bloodadvances.2017010819","article-title":"Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma","volume":"1","author":"Kim","year":"2017","journal-title":"Blood Adv."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2018","journal-title":"Lancet"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1758835920923829","DOI":"10.1177\/1758835920923829","article-title":"Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients","volume":"12","author":"Sun","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood-2019-127811","article-title":"Efficacy and Survival in Newly Diagnosed Advanced Extranodal Natural Killer\/T-Cell Lymphoma: A Randomized, Controlled, Multicenter and Open-Labled Study with Ddgp Regimen Versus SMILE Regimen","volume":"134","author":"Wang","year":"2019","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01","volume":"30","author":"Relander","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1007\/s00432-019-02999-9","article-title":"The role of autologous stem cell transplantation in peripheral T cell lymphoma: A long-term follow-up single-center experience","volume":"145","author":"Roerden","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/cncr.31861","article-title":"The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study","volume":"125","author":"Park","year":"2019","journal-title":"Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study","volume":"33","author":"Horwitz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study","volume":"29","author":"Pro","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1182\/blood-2018-99-115241","article-title":"The Combination of Duvelisib, a PI3K-\u03b4,\u03b3 Inhibitor, and Romidepsin Is Highly Active in Relapsed\/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts","volume":"132","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Huen, A., Haverkos, B.M., Zain, J., Radhakrishnan, R., Lechowicz, M.J., Devata, S., Korman, N.J., Pinter-Brown, L., Oki, Y., and Barde, P.J. (2020). Phase I\/Ib Study of Tenalisib (RP6530), a Dual PI3K \u03b4\/\u03b3 Inhibitor in Patients with Relapsed\/Refractory T-Cell Lymphoma. Cancers, 12.","DOI":"10.3390\/cancers12082293"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/cas.12735","article-title":"A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T-cell leukemia\/lymphoma","volume":"106","author":"Ishitsuka","year":"2015","journal-title":"Cancer Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood-2018-99-112123","article-title":"Durable Responses Observed with JAK Inhibition in T-Cell Lymphomas","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/leu.2008.77","article-title":"Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas","volume":"22","author":"Feldman","year":"2008","journal-title":"Leukemia"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2015-02-629543","article-title":"The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma","volume":"126","author":"Witzig","year":"2015","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2018-04-840538","article-title":"Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma","volume":"132","author":"Lemonnier","year":"2018","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood.2019001285","article-title":"Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: A multicenter phase 1 study","volume":"134","author":"Falchi","year":"2019","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1200\/JCO.18.00899","article-title":"Randomized Phase III Study of Alisertib or Investigator\u2019s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma","volume":"37","author":"Jacobsen","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00889-z","article-title":"Biomarker-driven management strategies for peripheral T cell lymphoma","volume":"13","author":"Mulvey","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1182\/blood-2018-99-119944","article-title":"The Novel SYK\/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed\/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma","volume":"132","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clml.2019.03.022","article-title":"Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma","volume":"19","author":"Barta","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1182\/blood-2019-132278","article-title":"A Phase I\/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)","volume":"134","author":"Iyer","year":"2019","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/10428190601137658","article-title":"Angioimmunoblastic T cell lymphoma: Treatment experience with cyclosporine","volume":"48","author":"Advani","year":"2007","journal-title":"Leuk. Lymphoma"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/leu.2009.198","article-title":"Inhibition of Syk protein tyrosine kinase induces apoptosis and blocks proliferation in T-cell non-Hodgkin\u2019s lymphoma cell lines","volume":"24","author":"Wilcox","year":"2009","journal-title":"Leukemia"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1200\/JCO.2017.73.4830","article-title":"Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children\u2019s Oncology Group Study","volume":"35","author":"Voss","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/nm.2966","article-title":"PDGFR blockade is a rational and effective therapy for NPM-ALK\u2013driven lymphomas","volume":"18","author":"Laimer","year":"2012","journal-title":"Nat. Med."},{"key":"ref_98","unstructured":"(2021, May 24). FDA Approves Crizotinib for Children and Young Adults with Relapsed or Refractory, Systemic Anaplastic Large Cell Lymphoma, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-crizotinib-children-and-young-adults-relapsed-or-refractory-systemic-anaplastic-large."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-09-2697","article-title":"Defucosylated Humanized Anti-CCR4 Monoclonal Antibody KW-0761 as a Novel Immunotherapeutic Agent for Adult T-cell Leukemia\/Lymphoma","volume":"16","author":"Ishii","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study","volume":"30","author":"Ishida","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1158\/1535-7163.MCT-16-0233","article-title":"ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer\u2013Containing Antibody\u2013Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies","volume":"15","author":"Flynn","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood-2018-99-115986","article-title":"Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Relapsed\/Refractory Non-Hodgkin Lymphoma Shows Activity in T-Cell Lymphoma","volume":"132","author":"Collins","year":"2018","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1182\/blood-2018-99-112076","article-title":"Alemtuzumab Added to CHOP for Treatment of Peripheral T-Cell Lymphoma (PTCL) in Previously Untreated Young and Elderly Patients: Pooled Analysis of the International ACT-1\/2 Phase III Trials","volume":"132","author":"Altmann","year":"2018","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","article-title":"A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid\u00ae) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial","volume":"49","author":"Morschhauser","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0167-4838(90)90139-7","article-title":"Bifunctional antibodies: Concept, production and applications","volume":"1040","author":"Nolan","year":"1990","journal-title":"Biochim. Biophys. Acta BBA Protein Struct. Mol. Enzym."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ymeth.2018.10.026","article-title":"Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety","volume":"154","author":"Ellerman","year":"2018","journal-title":"Methods"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed\/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.pharmthera.2018.09.008","article-title":"Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy","volume":"194","author":"Constantinidou","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1056\/NEJMc1803181","article-title":"Rapid Progression of Adult T-Cell Leukemia\u2013Lymphoma after PD-1 Inhibitor Therapy","volume":"378","author":"Ratner","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e000104","DOI":"10.1136\/jitc-2019-000104","article-title":"T-cell lymphoma secondary to checkpoint inhibitor therapy","volume":"8","author":"Anand","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1158\/1535-7163.MCT-17-0848","article-title":"ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1\/2 and XIAP, Potently Induces TNF\u03b1-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth","volume":"17","author":"Ward","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2147\/OTT.S33375","article-title":"IAP proteins as targets for drug development in oncology","volume":"9","author":"Dubrez","year":"2013","journal-title":"OncoTargets Ther."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/leu.2014.56","article-title":"Inhibitor of Apoptosis (IAP) proteins in hematological malignancies: Molecular mechanisms and therapeutic opportunities","volume":"28","author":"Fulda","year":"2014","journal-title":"Leukemia"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1158\/1078-0432.CCR-19-1430","article-title":"A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma","volume":"26","author":"Mita","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/hon.211_2631","article-title":"Preliminary results of astx660, a novel non-peptidomimetic ciap1\/2 and xiap antagonist, in relapsed\/refractory peripheral t-cell lymphoma and cutaneous T cell lymphoma","volume":"37","author":"Samaniego","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood-2006-11-059139","article-title":"Epstein Barr virus\u2013specific cytotoxic T lymphocytes expressing the anti-CD30\u03b6 artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease","volume":"110","author":"Savoldo","year":"2007","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial","volume":"23","author":"Wang","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor\u2013redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell receptor \u03b2-chain constant region for immunotherapy of T cell malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.ymthe.2017.06.012","article-title":"Engineering Natural Killer Cells for Cancer Immunotherapy","volume":"25","author":"Rezvani","year":"2017","journal-title":"Mol. Ther."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/22\/5627\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:28:18Z","timestamp":1760167698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/22\/5627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,10]]},"references-count":121,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["cancers13225627"],"URL":"https:\/\/doi.org\/10.3390\/cancers13225627","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,10]]}}}